Ian T. Bothwell - 10 Jun 2026 Form 4 Insider Report for Zeo ScientifiX, Inc. (ZEOX)

Reporting relationship: CEO & CFO, Director, 10%+ Owner
Issuer ticker: ZEOX
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 16:25:48 UTC
Prior SEC filing: 16 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Ian T. Bothwell

Key filing fact

Ian T. Bothwell filed Form 4 for Zeo ScientifiX, Inc. (ZEOX) on 12 Jun 2026.

Key facts

This page summarizes Ian T. Bothwell's Form 4 filing for Zeo ScientifiX, Inc. (ZEOX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Jun 2026, 16:25.

Change

Previous filing in this sequence was filed on 16 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001207638 Primary reporting owner

BOTHWELL IAN T

Relationship: CEO & CFO, Director, 10%+ Owner
Address: 3321 COLLEGE AVENUE, SUITE 246, DAVIE
Signature: /s/ Ian T. Bothwell
Signature date: 12 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZEOX transaction Derivative

Stock Options

Award

Transaction value
Shares: +625,000
Change %
Price: $0.000000^*
Shares after: 625,000
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 625,000
Exercise price: $1.67
Footnotes: F1

ZEOX transaction Derivative

Stock Options

Award

Transaction value
Shares: +625,000
Change %
Price: $0.000000^*
Shares after: 625,000
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 625,000
Exercise price: $1.67
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan"). The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan.

Footnote F2

Represents the grant of stock options to purchase shares of the Issuer's common stock under the 2021 Plan. The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis" during the period commencing on the date they vest and ending ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan. The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock outstanding on a fully diluted basis.